CALLIPER Trial for Progressive MS Enrolls First Patient

CALLIPER Trial for Progressive MS Enrolls First Patient

307882

CALLIPER Trial for Progressive MS Enrolls First Patient

Immunic Therapeutics has enrolled the first patient in a Phase 2 clinical trial testing its oral therapy candidate IMU-838 for the treatment of progressive multiple sclerosis (MS). The trial, CALLIPER (NCT05054140), is expected to run in parallel to the company’s two identically-designed Phase 3 trials, dubbed ENSURE-1 and ENSURE-2, to assess the therapeutic potential of IMU-838 in patients with relapsing-remitting MS (RRMS). According to Immunic, the ENSURE trials are expected to start by year’s end. “Enrollment…

You must be logged in to read/download the full post.